I had the pleasure of being able to attend the BIO Investor Forum this past week, and was able to hear from incredibly innovative Biotech CEO's discussing their pipeline. It was very compelling to hear more and more of these organizations mentioning some engagement with drugs that are being developed for specific rare diseases. I left the meeting very hopeful.
At The Project, we will be working to keep you all up to date on what is happening in this market, presenting the companies, the drugs, the trials that all will ultimately impact rare disease. We are in a very promising time in medicine.